|
WO2021030867A1
|
|
Method of modulating adiposity
|
|
WO2021007623A1
|
|
Compositions for maintaining or modulating mixtures of ether lipid molecules in a tissue of a human subject
|
|
WO2020237307A1
|
|
Chimeric molecules comprising an anti-coagulant agent and an anti-gpiib/iiia antigen binding molecule and uses thereof
|
|
WO2020237305A1
|
|
Binding proteins comprising the extracellular domain of cd39 and methods of treating or preventing neurological diseases
|
|
WO2020237304A1
|
|
Antigen-binding molecules that bind the active conformation of platelet integrin receptor gpiib/iiia
|
|
WO2019241847A1
|
|
A therapeutic gpiib/iiia binding-protein drug conjugate and use thereof
|
|
WO2019195892A1
|
|
Dementia risk analysis
|
|
US2021095048A1
|
|
Modulatory agents
|
|
WO2019119049A1
|
|
Method of predicting drug therapeutic responder status and methods of treatment
|
|
WO2019046903A1
|
|
A therapeutic method of increasing muscle mass in a subject
|
|
AU2016252887A1
|
|
Smad7 gene delivery as a therapeutic
|
|
AU2016214975A1
|
|
A method of treatment and compounds for use therein
|
